1. Scrip
  2. >>Conferences

Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH

Greater Combined Effect Seen In Phase III Trials

 
• By Joseph Haas

The firm revealed that an analysis of its Phase III ESSENCE trial combining fibrosis reduction and NASH resolution showed a higher effect over placebo than in Madrigal’s pivotal trial.

Novo Nordisk presented more data for semaglutide in NASH at AASLD (Shutterstock)

New data from Novo Nordisk’s Phase III ESSENCE study of semaglutide in non-alcoholic steatohepatitis (NASH) unveiled at the American Association for the Study of Liver Disease conference on 19 November showed that the GLP-1 agonist performed better than Madrigal’s Rezdiffra (resmetirom), the only approved NASH drug, in an analysis combining outcomes on the two primary endpoints, reduction of liver fibrosis and resolution of NASH.

Key Takeaways
  • Novo Nordisk presented new data from its Phase III ESSENCE study of semaglutide in NASH at AASLD, pointing to a possible efficacy advantage versus Rezdiffra.

The Danish pharma confirmed its plans to file semaglutide for approval in NASH – also known as metabolic dysfunction-associated steatohepatitis...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Conferences

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.